INVO Bioscience Reports Second Quarter 2021 Financial and Operating Results and Provides Business Update

SARASOTA, Fla., Aug. 16, 2021 /PRNewswire/ — INVO Bioscience, Inc. (Nasdaq: INVO), a medical device company focused on creating alternative…

SARASOTA, Fla., Aug. 16, 2021 /PRNewswire/ — INVO Bioscience, Inc. (Nasdaq: INVO), a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world’s only in vivo culture system, today announced financial and operating results for the second quarter ended June 30, 2021 and provides a business update.

Recent Operational Highlights

  • Officially opened the first U.S.-based INVO Center, located in Birmingham, Alabama in partnership with reproductive specialists Dr. Nicholas Cataldo, MD, MPH, Dr. Karen R. Hammond, DNP, CRNP, and Lisa Ray, MS, ELD. The new Birmingham practice, named «Innovative Fertility Specialists, an INVO Center» will provide fertility treatment utilizing the efficient, effective, and affordable INVOcell option. The practice has begun seeing patients and expects to perform initial treatment cycles in September 2021.
  • Signed a joint venture agreement with Bloom Fertility to open an INVO Center in Atlanta, Georgia. Led by reproductive specialist Dr. Sue Ellen Carpenter, M.D., the center is scheduled to open in September 2021.
  • Completed the site build-out and preparing to open the Company’s INVO Center JV in Monterrey, Mexico, Positib Fertility, with Drs. Francisco Arredondo and Ramiro Ramirez. Expected to open in the October timeframe.
  • Signed a partnership agreement with Lyfe Medical, LLC to establish and operate a clinic in the San Francisco Bay area to offer the INVO procedure. Lyfe Medical will own the clinic while INVO will set-up and manage an embryology center to provide laboratory services to the clinic and its patients in exchange for a share of the clinic’s revenue.
  • Expanded capabilities within the global OB/GYN vertical with the appointment of Barbara Levy, M.D., FACOG, FACS as the SVP, global clinical integration. Dr. Levy is considered one of the most influential reproductive health clinical executives in the world, recently serving as Vice President, Health Policy at the American College of Obstetricians and Gynecologists (ACOG) and chair of the American Medical Association/Specialty Society Relative Value Scale Update Committee.
  • Appointed Andrea Goren as CFO, replacing the Company’s past utilization of an outside CFO consulting firm, to lead the Company’s finance function and to support the execution of the Company’s strategic business plan, including the operational launch of the Company’s INVO Center joint ventures.

Financial Highlights

  • Revenues were $208,472 for the quarter ended June 30, 2021, compared to $246,072 for the quarter ended June 30, 2020.
  • Net loss for the second quarter of 2021 was approximately $(1.8) million, which included approximately $(0.7) million of non-cash charges primarily related to the debt discount amortization and equity-based compensation.
  • Adjusted EBITDA for the second quarter of 2021 was $(1.3) million, which included $93,969 of JV start-up costs, compared to $(0.8) million in the prior year’s second quarter (see Adjusted EBITDA Table).
  • As of June 30, 2021, the Company had a cash position of approximately $6.6 million.

Management Discussion

«Our team made excellent progress during the second quarter of 2021 toward our key objectives, headlined by last week’s official opening of our first INVO Center practice in Birmingham, Alabama,» commented Steve Shum, CEO of INVO Bioscience.  «We feel INVO is now well positioned for success based on the following core foundational elements developed over the past 2 years:

  1. Our Team – An experienced internal operating team with key positions filled, a strong and diverse board of directors, a scientific advisory board composed of well-known and respected fertility industry experts, and key outside KOL’s/consultants.
  2. Our Partners – A growing list of quality distributors around the world, experienced and motivated JV Partners, and a committed shareholder base.
  3. Our Technology – We have gained valuable real market usage data (and hence further validation) along with a clear understanding of how our technology «fits» in the industry and the key challenges it helps solve.

We believe there is a substantial underserved patient population with infertility challenges and a real need to expand access to treatment. In our opinion, this is a multi-billion-dollar market expansion opportunity, and INVOcell is well positioned to address the unmet medical need.»

«The new Birmingham practice, our very first INVO Center, is a major milestone and one of the most significant in the Company’s history to date.  The center is already off to an encouraging start as we have surpassed our internal expectations for patient appointments and expected treatment cycles planned for the first month. The vision to drive accelerated adoption of the INVOcell solution while also increasing much needed capacity and patient access within the fertility industry is coming to reality with this first INVO Center, thanks to the expertise and commitment of our internal team and partners.»

Mike Campbell, COO further added, «With the blueprints now firmly in place for our INVO Center model, we are rapidly moving towards the opening of centers in Atlanta, Monterrey, Mexico and the San Francisco Bay area. We expect that Atlanta and Monterrey centers will both be opened before the end of the year, as site selections are complete, equipment has been ordered, staffing is ramping up, and marketing plans are in place. A San Francisco Bay area center should be opened shortly thereafter and our ongoing discussions with additional partners remain active. This is an exciting time for INVO as we have diversified our business model beyond device sales exclusively through our distributors, to a model where we will capture a share of the larger revenue generated by the entire INVO patient solution.»

Shum concluded, «Our goal to democratize fertility treatment by bringing care to the vast underserved patient population around the world experiencing infertility challenges is advancing.  We believe a key to this effort will also involve leveraging the OB/GYN community.  In July, we appointed Dr. Barbara Levy as our SVP, global clinical integration. Dr. Levy is considered one of the most influential fertility and reproductive health clinical executives in the world and brings a life-long passion to improving women’s health recognizing that a critical component to that is treatment for infertility. I am excited to have Dr. Levy help lead this OB/GYN strategy moving forward.»

Financial Results

Revenues for the three months ended June 30, 2021 were approximately $0.21 million, compared to approximately $0.25 million for the same three-month period in 2020. The slight change was the result of a decrease in product sales to Ferring. Ferring’s minimum purchase requirements are based on a calendar year and hence contribute to quarterly fluctuations. Revenue pertaining to the Company’s INVO Centers will begin to be recognized in the current, third quarter.

Gross margin reported for the three months ended June 30, 2021 was approximately 93% compared to approximately 91% for the three months ended June 30, 2020.

Selling, general and administrative expenses for the three months ended June 30, 2021 were approximately $2.0 million compared to approximately $1.3 million for the three months ended June 30, 2020. The increase was primarily the result of increased personnel, board and business development consulting expenses, as well as startup costs related to our INVO Centers. We incurred approximately $0.6 million of non-cash, stock-based compensation expense in the period compared to $0.3 million for the same period in the prior year.

We began to fund additional R&D efforts in 2020 as part of our 5-day label expansion efforts. R&D expenses were $0.03 million for the three months ended June 30, 2021, compared to $0.03 million for the three months ended June 30, 2020.

Interest expense and financing fees were approximately $0.09 million for the three months ended June 30, 2021, compared to approximately $0.26 million for the three months ended June 30, 2020.

Net loss for the three months ended June 30, 2021 was approximately $(1.8) million compared to approximately $(1.3) million for the three months ended June 30, 2020. The increase in net loss was due to increased operating expenses.

Adjusted EBITDA (see Adjusted EBITDA Table) for the three months ended June 30, 2021 was $(1.3) million, compared to adjusted EBITDA of $(0.8) million for the three months ended June 30, 2020.

As of June 30, 2021, the Company had approximately $6.6 million in cash compared to approximately $8.4 million on March 31, 2021.

Use of Non-GAAP Measure

Adjusted EBITDA is a non-GAAP measure. This measure is not intended to be a substitute for those financial measures reported in accordance with GAAP. Adjusted EBITDA has been included because management believes that, when considered together with the GAAP figures, it provides meaningful information related to our operating performance and liquidity and can enhance an overall understanding of financial results and trends. Adjusted EBITDA may be calculated by us differently than other companies that disclose measures with the same or similar terms. See our attached financials for a reconciliation of this non-GAAP measure to the nearest GAAP measure.

Conference Call Details

INVO Bioscience has scheduled a conference call for Monday, August 16, 2021, at 4:30 pm ET (1:30 pm PT) to review these results and recent events. Interested parties can access the conference call by dialing (833) 756-0861 or (412) 317-5751 or can listen via a live Internet webcast at  https://www.webcaster4.com/Webcast/Page/2162/42110, which is also available in the Investor Relations section of the Company’s website at https://www.invobioscience.com/investors/.

A teleconference replay of the call will be available through August 23, 2021 at (877) 344-7529 or (412) 317-0088, confirmation #10158496. A webcast replay will be available in the Investor Relations section of the Company’s website at https://www.invobioscience.com/investors/ for 90 days.

About INVO Bioscience

We are a medical device company focused on creating simplified, lower-cost treatments for patients diagnosed with infertility. Our solution, the INVO® Procedure, is a revolutionary in vivo method of vaginal incubation that offers patients a more natural and intimate experience. Our lead product, the INVOcell®, is a patented medical device used in infertility treatment and is considered an Assisted Reproductive Technology (ART). The INVOcell® is the first Intravaginal Culture (IVC) system in the world used for the natural in vivo incubation of eggs and sperm during fertilization and early embryo development, as an alternative to traditional In Vitro Fertilization (IVF) and Intrauterine Insemination (IUI). Our mission is to increase access to care and expand fertility treatment across the globe with a goal to lower the cost of care and increase the availability of care. For more information, please visit http://invobioscience.com/

Safe Harbor Statement

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as «anticipate,» «if,» «believe,» «plan,» «estimate,» «expect,» «intend,» «may,» «could,» «should,» «will,» and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

INVO BIOSCIENCE, INC.

CONSOLIDATED BALANCE SHEETS

(UNAUDITED)




 June 30, 2021 



 December 31,

2020 







ASSETS






Current assets






Cash

$

6,643,080


$

10,097,760

Accounts receivable


47,869



21,699

Inventory


250,784



265,372

Prepaid expenses and other current assets


289,843



157,700

Total current assets


7,231,576



10,542,531

Property and equipment, net


127,151



132,206

Capitalized patents, net


22,155



5,427

Lease right of use


1,419,925



79,319

Trademarks


107,287



89,536

Notes receivable


881,827



Other assets




240

Investment in joint ventures


141,267



98,084

Total assets

$

9,931,188


$

10,947,343







LIABILITIES AND STOCKHOLDERS’ EQUITY






Current liabilities






Accounts payable and accrued liabilities, including related parties

$

306,252


$

328,927

Accrued compensation


349,658



527,326

Deferred revenue, current portion


714,286



714,286

Lease liability, current portion


96,921



22,707

Note payable – Payroll Protection Program




157,620

Convertible notes, net


249,936



536,063

Income taxes payable




1,062

Total current liabilities


1,717,053



2,287,991

Lease liability, net of current portion


1,355,323



58,634

Deferred revenue, net of current portion


2,500,000



2,857,143

Deferred tax liability


469



469

Total liabilities


5,572,845



5,204,237







Stockholders’ equity






Common Stock, $.0001 par value; 125,000,000 shares authorized; 10,459,035 and 9,639,268

issued and outstanding as of June 30, 2021 and December 31, 2020, respectively


1,046



964

Additional paid-in capital


40,864,011



37,978,224

Accumulated deficit


(36,506,714)



(32,236,082)

Total stockholders’ equity


4,358,343



5,743,106







Total liabilities and stockholders’ equity

$

9,931,188


$

10,947,343

 

INVO BIOSCIENCE, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)




For the Three Months Ended

June 30,


For the Six Months Ended

June 30,




2021



2020



2021



2020

Revenue:













Product revenue


$

29,900


$

67,500


$

535,852


$

147,500

License revenue



178,572



178,572



357,143



357,143

Total revenue


$

208,472


$

246,072


$

892,995


$

504,643

Cost of goods sold:













Production costs



12,163



18,739



72,477



46,301

Depreciation



2,432



2,431



4,863



4,863

Total cost of goods sold



14,595



21,170



77,340



51,164

Gross profit



193,877



224,902



815,655



453,479

Operating expenses













Selling, general and administrative



2,049,422



1,252,939



4,164,725



2,847,985

Research and development



31,016



34,890



97,283



64,940

Total operating expenses



2,080,438



1,287,829



4,262,008



2,912,925

Loss from operations



(1,886,561)



(1,062,927)



(3,446,353)



(2,459,446)

Other income (expense):













Other income



159,126





159,126



Interest income



2,425





4,438



Interest expense



(91,125)



(259,954)



(986,351)



(307,827)

Foreign currency exchange  loss



(1,028)





(1,492)



Total other income (expense )



69,398



(259,954)



(824,279)



(307,827)

Loss before income taxes



(1,817,163)



(1,322,881)



(4,270,632)



(2,767,273)

Provision for income taxes









Net loss


$

(1,817,163)


$

(1,322,881)


$

(4,270,632)


$

(2,767,273)














Net loss per common share:













Basic


$

(0.17)


$

(0.27)


$

(0.42)


$

(0.56)

Diluted


$

(0.17)


$

(0.27)


$

(0.42)


$

(0.56)

Weighted average number of

common shares outstanding:













Basic



10,444,150



4,932,942



10,167,624



4,925,469

Diluted



10,444,150



4,932,942



10,167,624



4,925,469

 


Adjusted EBITDA





Three Months Ended


Six Months Ended



June 30


June 30



2021


2020


2021


2020









Net Loss

$                (1,817,163)


$                 (1,322,881)


$                (4,270,632)


$                 (2,767,273)


Other Income

(159,126)



(159,126)



Interest expense

9,707


(2,991)


44,778


44,882


Foreign currency exchange  loss

1,492



1,492



Stock-based compensation

235,144


65,309


427,208


406,772


Stock option expense

384,083


214,915


760,606


596,390


Amortization of debt discount

76,980


223,027


937,135


262,945


Depreciation and amortization

(2,695)


(2,551)


5,959


5,958

Adjusted EBITDA*

$                (1,271,579)


$                    (825,172)


$                (2,252,580)


$                 (1,450,326)











*Adjusted to also include non-cash, stock-based expensing

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/invo-bioscience-reports-second-quarter-2021-financial-and-operating-results-and-provides-business-update-301356114.html

SOURCE INVO Bioscience, Inc.